Cargando…

Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO‐ABLE study

BACKGROUND: Fixed combination calcipotriol 50 μg/g (Cal) plus betamethasone 0.5 mg/g (BD) foam has been developed as a new treatment option for patients with psoriasis. METHODS: The randomized, parallel‐group, investigator‐blinded Phase III, 12‐week PSO‐ABLE study compared the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paul, C., Stein Gold, L., Cambazard, F., Kalb, R.E., Lowson, D., Bang, B., Griffiths, C.E.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Psoriasis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6207928/ https://www.ncbi.nlm.nih.gov/pubmed/27531752 http://dx.doi.org/10.1111/jdv.13859

Ejemplares similares

Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching‐adjusted indirect comparison
por: Bewley, A.P., et al.
Publicado: (2019)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study
por: Paul, Carle, et al.
Publicado: (2017)

Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study
por: Koo, John, et al.
Publicado: (2016)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
por: Anderko, Marian, et al.
Publicado: (2019)

Non‐invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator‐initiated, phase IV, unicentric, open, randomized clinical trial
por: Yélamos, O., et al.
Publicado: (2020)

Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
por: Vakirlis, Efstratios, et al.
Publicado: (2008)

Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature
por: Pinter, Andreas, et al.
Publicado: (2018)

Safety and efficacy of fixed‐dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open‐label trial
por: Seyger, M., et al.
Publicado: (2020)

Efficacy of an Innovative Aerosol Foam Formulation of Fixed Combination Calcipotriol plus Betamethasone Dipropionate in Patients with Psoriasis Vulgaris
por: Queille-Roussel, Catherine, et al.
Publicado: (2015)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis
por: Stein Gold, Linda, et al.
Publicado: (2016)

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Compared with Betamethasone 17-Valerate-Medicated Plaster for the Treatment of Psoriasis
por: Queille-Roussel, Catherine, et al.
Publicado: (2016)

Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment
por: Rudnicka, Lidia, et al.
Publicado: (2021)

Editorial: fixed‐dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis
por: Lebwohl, M., et al.
Publicado: (2021)

Quality of life and patient‐perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed‐dose combination Cal/BD foam: A post‐hoc analysis of PSO‐LONG
por: Jalili, A., et al.
Publicado: (2021)

Secukinumab efficacy in reducing the severity and the psychosocial impact of moderate‐to‐severe psoriasis as assessed by the Simplified Psoriasis Index: results from the IPSI‐PSO study
por: Richard, M.‐A., et al.
Publicado: (2020)

Real-World Experience Using Topical Therapy—Calcipotriol and Betamethasone Dipropionate Foam in Adults with Beyond-Mild Psoriasis
por: Aschoff, Roland, et al.
Publicado: (2021)

Beyond-Mild Psoriasis: A Consensus Statement on Calcipotriol and Betamethasone Dipropionate Foam for the Topical Treatment of Adult Patients
por: Aschoff, Roland, et al.
Publicado: (2021)

Improvement of health-related quality of life and adherence to treatment with calcipotriol-betamethasone dipropionate gel in patients with psoriasis vulgaris
por: Kontochristopoulos, George, et al.
Publicado: (2016)

Enhanced vasoconstrictor potency of the fixed combination calcipotriol plus betamethasone dipropionate in an innovative aerosol foam formulation vs. other corticosteroid psoriasis treatments
por: Queille‐Roussel, C., et al.
Publicado: (2016)

Efficacy of Calcipotriol/Betamethasone Dipropionate Fixed-Combination Aerosol Foam in the Treatment of Localized Scalp Psoriasis: A Real-Life Case Series from Switzerland
por: Régnier, Antonia, et al.
Publicado: (2022)

Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
por: Navarro-Triviño, Francisco José, et al.
Publicado: (2021)

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)
por: Seneschal, J., et al.
Publicado: (2020)

A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris
por: Taraska, Victoria, et al.
Publicado: (2016)

Patient satisfaction and efficacy of calcipotriol plus betamethasone dipropionate gel in plaque psoriasis patients with poor adherence
por: Takahashi, Hidetoshi, et al.
Publicado: (2020)

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review
por: Torres, Tiago, et al.
Publicado: (2023)

Efficacy of calcipotriol plus betamethasone dipropionate foam on psoriatic skin lesions beyond human eyes: An observational study
por: Anna, Campanati, et al.
Publicado: (2022)

Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real‐life multicenter prospective observational cohort study
por: Campanati, Anna, et al.
Publicado: (2021)

Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review
por: Patel, Nupur U, et al.
Publicado: (2017)

Calcipotriol and betamethasone dipropionate synergistically enhances the balance between regulatory and proinflammatory T cells in a murine psoriasis model
por: Satake, Kyosuke, et al.
Publicado: (2019)

Calcipotriol/betamethasone foam for proactive management of plaque psoriasis: four case reports
por: Apalla, Zoe, et al.
Publicado: (2022)

Long‐term proactive management of psoriasis with calcipotriol and betamethasone dipropionate foam: an Italian consensus through a combined nominal group technique and Delphi approach
por: De Simone, Clara, et al.
Publicado: (2022)

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study
por: Rungapiromnan, W., et al.
Publicado: (2019)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
por: Papp, K.A., et al.
Publicado: (2018)

Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials
por: Hampton, P., et al.
Publicado: (2021)

Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review
por: Narbutt, Joanna, et al.
Publicado: (2021)

Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation
por: Colombo, Giorgio L, et al.
Publicado: (2012)

Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
por: Gooderham, M, et al.
Publicado: (2014)

Efficacy and Safety of Calcipotriol/Betamethasone Dipropionate Ointment for the Treatment of Trachyonychia: An Open-Label Study
por: Park, Jung-Min, et al.
Publicado: (2015)

Early efficacy and safety data with fixed‐dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency
por: Tada, Y., et al.
Publicado: (2021)

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross‐sectional analysis from the US‐based Corrona Psoriasis Registry
por: Mease, P.J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8kse7bsold2i8u37hdvtgq4vug